Highlights from last week in the Biosphere 🌐
- Bio's $6.9M Round: Bio raised $6.9M in a fundraising round anchored by Arthur Hayes' Maelstrom Fund with participation from leading biotech and crypto investors. The funding will fuel Bio's growth into a full-stack platform for AI-driven DeSci, giving researchers, patients and the crypto community new ways to build and monetize biotech discoveries outside traditional pharma structures and faster than legacy biotech. The round coincides with the introduction of new primitives like BioAgents and new onchain funding, incentive and AI-driven frameworks to early-stage scientific research & development. Press coverage in Cointelegraph, CoinDesk, TheBlock, Longevity Technology & The Associated Press (AP).
- New Ignition Sales: The second and third Ignition Sales went live on the Bio Launchpad: $BiomeAI (@BioameAI), a BioAgent for personalized microbiome health & trials and $eDMT (@edmtcomms), an IP-Token exploring natural DMT production in the brain launched in partnership with a University of Florida lab. Both sales last 3 days and close in roughly 24 hours, on Monday, September 22, 2025 at approximately 13:30 UTC. In their first hours live, both sales were oversubscribed, enabling BioXP and $BIO holders who participated to receive early allocations. Both tokens will go live for secondary-market trading shortly after the sales conclude via AMM liquidity pools paired with BIO. Ignition Sale access and open market trading is available in the Bio App, via the BiomeAI page and the eDMT page.
- DeSci Lending: Bio's DeFi team proposed deploying 1.5M BIO to bootstrap a lending market for BIO on @aave V3, enabling BIO to be used as collateral for loans or to be lent out to earn yield, while deepening the integration of BIO within the DeFi ecosystem.
- Aubrai Research Funding: @Aubrai_, the first BioAgent, recently crossed $275K in monthly research funding generated from market-making fees in the $AUBRAI token. This funding is directed to the lab of Dr. @aubreydegrey and its ongoing RMR2 Life Extension study feeding data into the agent. In its first weeks live, Aubrai has generated over 1,100 hypotheses which are now under evaluation by researchers at @vita_dao and Dr. de Grey's lab. The most promising hypotheses will be advanced as experiments and financed as IP Tokens on the Bio launchpad. Submit a longevity research proposal to Aubrai to qualify for up to $100K in funding, with 20K BIO awarded for researcher referrals.
- BioXP Updates: A new round of BioXP was distributed in the Bio App covering yaps before September 10. Bio's Head of Tech @elliossios discussed efforts to build BioXP as a powerful DeSci loyalty system that incentivizes authentic contributions, new insights and scientific/technical discourse to help the Bio community grow. Keep staking and yapping to earn BioXP, with daily staking XP and weekly yapping BioXP distributions, as well as upcoming BioXP "Boost" campaigns rewarding specific contributions & behaviors.
🌐 Ecosystem Updates
- Cerebrum DAO's Transfidelity project is testing their compounds across cell types and developing a Parkinson's disease model using stem cells, targeting completion by December, followed by early 2026 tests in neurons and molecular analyses. They also shared how they're advancing the world's first tokenized brain health supplement, backed by several patents and available on Amazon and in Walmart.
- VitaDAO will fund development of RNA molecules that advance the longevity-linked FOXO3 gene to address degenerative disc disease (a leading cause of disability). Separate funding was proposed to advance VitaRNA's lead AAV9 gene therapy for aging into non-GLP toxicology studies in non-human primates by the end of 2025.
- Curetopia completed drug screens for 10 ARS genes and secured data for a foundational patent in the form of a forthcoming IP-NFT & will soon turn them into IPTs funding their ARS pipeline. Learn more in their lab meeting
- Quantum Biology DAO successfully tested and calibrated their quantum microscope, controlling the magnetic field it produces with Python code.
- D1ckDAO onboarded over 12,000 users to their BioAgent, D1ckGPT, with more than 10,000 completing the D-Age assessment.
- AthenaDAO announced AthenaBIO, an equity vehicle announced in an exclusive with FutureFemHealth, backing 15 early-stage assets in AI, diagnostics, ovarian health, and ReproTech.
- SpineDAO team members presented at the Scoliosis Research Society, a prestigious event uniting spine clinicians & innovators worldwide. They also expanded their Creators Hub, seeking contributors and content creators to drive global discussions on spinal health.
Bio Community Updates
- Bio Asia Tour: The Bio team is touring Asia this month and next month, with DeSci summits, a bio/acc rave, and countless IRL meetings with key partners and scientists. RSVP and view the event schedule.
- Bio & Pump Science joined the @therollupco podcast to discuss the latest DeSci updates.
- AUBRAI liquidity was migrated to Aerodrome & staked to earn emissions.
- DeSci Lisbon took place on September 18, hosted by Bio, Cerebrum DAO, MicrobiomeDAO, PsyDAO, AxonDAO & Elata.
- The Bio team hosted a spaces discussing BiomeAI and eDMT, the new Ignition Sales on Bio's launchpad.
- Bio's Head of AI @AakaashMeduri attended @base BaseCamp
- Bio is hiring a chief of staff with 100K BIO for successful referrals.
🧪 Explore New DeSci projects on the Bio App.
Stay updated via our Telegram, Discord & Governance forum. Follow @BioProtocolEco on X for real-time ecosystem updates.
